[A17-19] Alectinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Last updated 01.08.2017
Project no.:
A17-19
Commission:
Commission awarded on 01.05.2017 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Indication:
Advanced ALK-positive NSCLC (lung cancer)
Result of dossier assessment:
Added benefit not proven, as no (or no suitable) data available
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A17-44 | Alectinib (non-small-cell lung cancer) - Addendum to commission A17-19 | Commission completed |
| A24-73 | Alectinib (NSCLC, adjuvant) – Benefit assessment according to §35a Social Code Book V | Commission completed |